Newly developed retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the weight loss community. Initial clinical research have demonstrated substantial losses in physical mass and gains in physiological markers for people with overweight. Researchers believe this ground-brea